Application of combined use of bilirubin, chondroitin sulfate and licosalone in preparation of medicine for treating osteoarthritis and sequential targeted medicine delivery system for treating arthritis

Through the combination of bilirubin-modified chondroitin sulfate and Likfelon, nanoparticles targeting M1 macrophages were prepared, which solved the problems of short drug retention time and lack of targeting in existing osteoarthritis treatment methods, and achieved the The effective treatment of osteoarthritis and the repolarization of M1 macrophages have been significantly improved in therapeutic effect.

CN118903187AActive Publication Date: 2024-11-08XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411268650.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-08
Estimated Expiration
2044-09-11

AI Technical Summary

Technical Problem

The existing treatment methods for osteoarthritis lack safe and effective methods to delay the progress of the disease. Likfeldon, as a non-steroidal anti-inflammatory drug, has potential adverse reactions, and lacks targeting the effects of cells and organelles, and is easy to be in the joints. It is cleared and the joint retention time is short.

Method used

Using bilirubin-modified chondroitin sulfate and rikfelon, nanoparticles were prepared through the modification process of ethylenediamine and bilirubin, forming a sequential targeted drug delivery system, using chondroitin sulfate and M1 macrophages. CD44 receptor binds to the Golgi body of M1 macrophages, reduces Golgi body stress, regulates sphingolipid metabolism and AA metabolism disorders, and realizes the repolarization of M1 macrophages into M2 macrophages.

Benefits of technology

It has achieved effective treatment of osteoarthritis, prolonged the retention time of Likfly in the joints, reduced the ROS level, corrected the polarization state of M1 macrophages, reduced joint pain, and relieved the inflammatory response of OA. And significantly improve the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903187A_ABST
    Figure CN118903187A_ABST
Patent Text Reader

Abstract

The invention provides application of combined use of bilirubin, chondroitin sulfate and likefeeder in preparation of a medicine for treating osteoarthritis. The invention further provides a sequential targeted drug delivery system for treating arthritis, the sequential targeted drug delivery system is prepared from the bilirubin, the chondroitin sulfate and the licosalone as raw materials, and the molar ratio of the bilirubin to the chondroitin sulfate to the licosalone is as follows: 1 to 10 parts of the bilirubin, 1 to 20 parts of the chondroitin sulfate and 0.1 to 5 parts of the licosalone. The invention also provides a preparation method and application of the sequential targeted drug delivery system. According to the invention, synthesis of chondroitin sulfate modified by bilirubin is discovered for the first time, and licosenger is entrapped by polymer self-assembled micelles, so that sequential drug delivery is realized, and abnormal sphingolipid metabolism and AA metabolism of M1 type macrophages are efficiently regulated and controlled, so that the M1 type macrophages are converted into M2 type macrophages. In addition, the delivery system provided by the invention can prolong the retention and action time of the liketalone in the joint.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the use of bilirubin, chondroitin sulfate and lexafilon in combination in preparing a medicine for treating osteoarthritis, and a sequential targeted drug delivery system for treating arthritis, belonging to the field of medicines. Background Art

[0002] Osteoarthritis (OA) is a degenerative disease with joint pain as the main symptom caused by fibrosis, cracking, ulceration and loss of articular cartilage caused by multiple factors. It often affects the knee joint, hip joint, spine and hands. Its pathological characteristics are mainly degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic changes, bone hyperplasia at the joint edge and synovitis. OA seriously affects the joint function and quality of life of patients. Studies have found that OA, especially symptomatic knee OA, can significantly increase the all-cause mortality of patients. Unfortunately, there is currently no safe and effective treatment method that can delay the progression of OA at home and abroad.

[0003] Chondroitin sulfate is a natural component of cartilage that is usually extracted from shark or cow cartilage or synthesized. It has been widely studied in the treatment of osteoarthritis and is often used in combination with glucosamine. There is evidence that the combination of chondroitin sulfate and glucosamine can reduce joint pain, improve joint mobility, and may reduce the dose of conventional anti-inflammatory medications, especially when used for 6 to 24 months. Chondroitin sulfate has no clear benefit when used alone, but when combined with glucosamine, it may provide some relief for people with moderate to severe knee pain.

[0004] Bilirubin is a metabolite of hemoglobin and is usually related to liver function. Clinically, some blood or liver diseases can be detected by checking the bilirubin level in the blood. Bilirubin tests include indirect bilirubin and direct bilirubin, and the sum of the two is called total bilirubin. Changes in bilirubin levels can reflect the status of multiple organs and tissues, such as excessive destruction of red blood cells, hepatocyte bilirubin transport disorders, glucuronic acid conjugation defects, and bile duct obstruction.

[0005] At present, there are literature reports that oral convertible bilirubin self-assembly system is used for targeted treatment of colitis (Advanced Healthcare Materials (lF10.0) Pub Date: 2023-06-15, DOl: 10.1002 / adhm.202300946), which discloses that chondroitin sulfate can effectively mediate the construction of BR self-assembled nanomedicines (BSNMs) for the treatment of colitis through the intermolecular hydrogen bonds between the dense sulfate and carboxyl groups of chondroitin sulfate and the imino groups of BR.

[0006] There are currently no reports on the use of bilirubin-modified chondroitin sulfate for osteoarthritis.

[0007] Licofelone is a compound with anti-inflammatory properties. It is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) and has potential application in the treatment of osteoarthritis (OA). According to its chemical properties, licofelone has a melting point of 162-163°C, a density of 1.23, and usually exists in a solid form with a color of light yellow to nearly white. Licofelone showed inhibitory concentrations (IC50) of 0.16μM and 0.23μM for human platelet COX and 5-LOX, respectively, in in vitro studies. As a potential drug for the treatment of osteoarthritis, licofelone showed an anti-inflammatory effect comparable to methylprednisolone in experiments, and had a similar effect as celecoxib in reducing the content of the inflammatory factor prostaglandin E2 (PGE2). However, there may also be some defects or limitations in clinical applications. As a nonsteroidal anti-inflammatory drug, levofloxacin may have potential adverse reactions similar to other NSAIDs, especially long-term use may cause adverse effects on the gastrointestinal tract, cardiovascular system and kidneys (Guo Binsheng, et al., Research Progress in Drug Therapy for Osteoarthritis, Pharmaceutical Progress, 2018, 42(9): 679-703, Zhang Hongxia, Research on the Anti-inflammatory Effect of Levofloxacin, Modern Drugs and Clinics, July 2013, Vol. 28, No. 4). In addition, levofloxacin does not have targeted effects on cells and organelles. Moreover, levofloxacin is easily cleared in the joints and has a short joint retention time. Summary of the invention

[0008] The present invention provides a new use of bilirubin, chondroitin sulfate and lexapro in combination, and also provides a sequential targeted drug delivery system for treating arthritis.

[0009] The present invention provides the use of bilirubin, chondroitin sulfate and lexafilon in combination in the preparation of a medicine for treating osteoarthritis. The medicine is a medicine for relieving osteoarthritis joint pain.

[0010] Wherein, the molar ratio of bilirubin, chondroitin sulfate and lexapro is:

[0011] 1-10 parts of bilirubin, 1-20 parts of chondroitin sulfate, and 0.1-5 parts of lexapro.

[0012] Further preferably, the molar ratio of bilirubin, chondroitin sulfate and lexapro is:

[0013] 15 parts of bilirubin, 15 parts of chondroitin sulfate, and 27 parts of lexapro.

[0014] The medicine is a preparation for intra-articular administration.

[0015] The present invention also provides a sequential targeted drug delivery system for treating arthritis, which is prepared from bilirubin, chondroitin sulfate and levofloxacin as raw materials, wherein the molar ratio of bilirubin, chondroitin sulfate and levofloxacin is:

[0016] 1-10 parts of bilirubin, 1-20 parts of chondroitin sulfate, and 0.1-5 parts of lexapro.

[0017] Further preferably, the molar ratio of bilirubin, chondroitin sulfate and lexapro is:

[0018] 15 parts of bilirubin, 15 parts of chondroitin sulfate, and 27 parts of lexapro.

[0019] The sequential targeted drug delivery system of the present invention is to first modify chondroitin sulfate with bilirubin, and then encapsulate lexanol with the modified chondroitin sulfate to prepare nanoparticles LCF-CSBN containing lexanol, which is the sequential targeted drug delivery system of the present invention.

[0020] The present invention also provides a method for preparing the sequential targeted drug delivery system for treating arthritis, which comprises the following steps:

[0021] a. Ethylenediamine modified chondroitin sulfate:

[0022] First, chondroitin sulfate, carbodiimide hydrochloride, 4-dimethylaminopyridine and ethylenediamine are dissolved in N,N-dimethylformamide, reacted under magnetic stirring at room temperature, dialyzed in water to remove unreacted ethylenediamine and catalyst, and lyophilized to obtain ethylenediamine-modified chondroitin sulfate;

[0023] b. Bilirubin-modified chondroitin sulfate:

[0024] Dissolve bilirubin, EDCI, carbodiimide hydrochloride, and 4-dimethylaminopyridine in dimethyl sulfoxide, and react under magnetic stirring at room temperature. Dissolve the chondroitin sulfate modified with ethylenediamine in step a in a mixed solution of DMSO and water, and add the solution to the above reaction solution. React under magnetic stirring at 30° C., and pass nitrogen gas through the entire reaction system for protection. After the reaction is completed, dialyze in water to remove the organic reagent, and then remove the unreacted precipitate by centrifugation. After the supernatant is freeze-dried, the bilirubin-modified chondroitin sulfate is obtained.

[0025] c. Preparation of Liquefied Nanoparticles:

[0026] Dissolve levofloxacin in dimethyl sulfoxide, and then add the solution dropwise to the bilirubin-modified chondroitin sulfate aqueous solution prepared in step b under stirring. After the addition is completed, continue stirring, then use probe ultrasound to remove unencapsulated levofloxacin, i.e., levofloxacin nanoparticles (LCF-CSBN), by ultrafiltration.

[0027] The present invention also provides use of the sequential targeted drug delivery system in preparing a bone-joint cavity drug for treating osteoarthritis.

[0028] The invention provides a pharmaceutical composition for treating osteoarthritis, which comprises the sequential targeted drug delivery system.

[0029] Macrophages are an important part of the innate immune system. In different physiological and pathological environments, the cells can show functional plasticity according to different stimuli. Macrophages play an important role in maintaining various homeostatic functions of the body, such as tissue homeostasis, tissue remodeling, metabolic regulation, and host inflammatory defense. There are two different polarization states of macrophages, namely M1 macrophages (classical activated macrophages) and M2 macrophages (alternative activated macrophages). In OA joints, the infiltration and activation of M1 macrophages are the main characteristics. The excessive polarization of M1 macrophages plays an important role in the formation and maintenance of the inflammatory microenvironment of OA joints. Therefore, selectively enhancing the transformation of macrophages from M1 to M2 phenotypes may inhibit low-grade inflammation and inhibit the progression of OA. Cell metabolism plays an important regulatory role in the activation and function of macrophages. Generally, high concentrations of reactive oxygen species (ROS) in M1 macrophages can lead to Golgi stress, which in turn triggers abnormal lipid metabolism (especially sphingolipid metabolism); at the same time, arachidonic acid (AA), a precursor of various inflammatory mediators, also undergoes abnormal metabolism in M1 macrophages, and abnormal AA metabolism can further promote oxidative stress. Therefore, this lipid metabolism disorder in macrophages promotes M1 macrophage polarization through compensatory pathways of inflammatory and oxidative stress responses. Therefore, it is necessary to simultaneously regulate abnormal sphingolipid metabolism and AA metabolism in macrophages to effectively achieve the transformation of M1 macrophages to M2 macrophages.

[0030] The present invention couples bilirubin and chondroitin sulfate to obtain an amphiphilic polymer, which can self-assemble into nano micelles, and the nanoparticles are loaded with levofloxacin. The drug delivery system can bind to the CD44 receptor of M1 macrophages through chondroitin sulfate to achieve targeted drug delivery of M1 macrophages. Further, the drug delivery system can target the Golgi apparatus of M1 macrophages. After reaching the Golgi apparatus, bilirubin removes ROS to reduce Golgi stress, thereby regulating Golgi-related sphingolipid metabolism disorders. When bilirubin is oxidized, its hydrophilicity increases significantly, thereby causing the self-assembled nano micelles to disaggregate and release levofloxacin. Levofloxacin regulates M1 macrophage AA metabolism disorders by binding to cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) in cells. Ultimately, by simultaneously correcting the disorders of sphingolipid metabolism and AA metabolism, M1 macrophages can be repolarized into M2 macrophages, thereby achieving the treatment of OA. There are no reports on the use of sequential targeted drug delivery systems to repolarize M1 macrophages into M2 macrophages for the treatment of OA.

[0031] The present invention is the first to discover synthetic bilirubin-modified chondroitin sulfate, and to encapsulate levofloxacin through the polymer self-assembled micelles, thereby achieving sequential drug delivery, efficiently regulating the sphingolipid metabolism and AA metabolism abnormalities of M1 macrophages, thereby converting them into M2 macrophages. In addition, the delivery system of the present invention can prolong the retention and action time of levofloxacin in the joints. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 .CS-BR 1 H NMR spectrum;

[0033] Figure 2 .Characterization of LCF-CSBN. A) Particle size distribution of LCF-CSBN; B) Stability of LCF-CSBN at 4°C; c) Particle size of CS-BR at different concentrations; D) Changes in the amount of BR in LCF-CSBN over time in H2O2 (5mM), 2,2'-azobisisobutylamidine dihydrochloride (AAPH, 100mM) and NaOCl (1mM); E) Particle size of LCF-CSBN after storage in an environment containing ROS for 1h; F) Transmission electron microscopy of LCF-PEGBN after storage in a solution containing AAPH (100mM) for 1h; G) Transmission electron microscopy of LCF-CSBN after storage in a solution containing AAPH (100mM) for 1h;

[0034] Figure 3.Cellular uptake test of CSBN. A) Laser confocal microscopy observation of the uptake of CSBN and PEGBN in LPS-activated RAW264.7 cells; B) Laser confocal microscopy observation of the co-localization of CSBN, PEGBN and the Golgi apparatus of LPS-activated RAW 264.7 cells; C) Flow cytometry quantitative analysis bar graph of the uptake of CSBN and PEGBN by LPS-activated RAW 264.7 cells (n=3), ****P<0.0001; D) The uptake pathway of CSBN in LPS-activated RAW 264.7 cells (n=3), ****P<0.0001; E) Pearson correlation coefficient of the co-localization of CSBN, PEGBN and the Golgi apparatus of LPS-activated RAW 264.7 cells (n=3), ****P<0.0001;

[0035] Figure 4 .In vitro biological activity test of LCF-CSBR. A) Intracellular ROS concentration after LCF-CSBR treatment (DCF green staining); B) Laser confocal image of Golgi apparatus of cells after LCF-CSBR treatment; C) GOLPH3 green fluorescence staining results after LCF-CSBR treatment; D) GM130 green fluorescence staining results after LCF-CSBR treatment; E) iNOS red fluorescence and CD206 green fluorescence staining results after LCF-CSBR treatment; F) Cytokine concentration of cell culture supernatant after LCF-CSBR treatment, ****P<0.0001;

[0036] Figure 5 .Retention and distribution test of CSBN in OA joints. A) Small animal in vivo fluorescence imaging of CSBN in OA rat joints; B) Semi-quantitative bar graph of CSBN in OA rat joints (n=5); C) Area under the drug-dose curve (AUC, n=5) of CSBN in OA rat joints, ****P<0.0001; D) Co-localization of CSBN and synovial M1 macrophages in OA joints;

[0037] Figure 6 .The number of M1 and M2 macrophages in OA joints after LCF-CSBN treatment (n=5). A) Fluorescence co-staining of CD68 and iNOS (M1 type) and CD68 and CD206 (M2 type) in OA joint synovium; B) The proportion of M1 macrophages in OA joint synovium, ***P<0.001, ****P<0.001; C) The proportion of M2 macrophages in OA joint synovium, ****P<0.001;

[0038] Figure 7. Mechanical paw withdrawal threshold of OA model rats after LCF-CSBN treatment (n=7). *P<0.05, ***P<0.001, ****P<0.0001, LCF-CSBN group compared with Saline group; & P<0.05, &&&& P<0.0001, LCF-CSBN group compared with LCF group; $$$$P<0.0001, LCF-CSBN group compared with CSBN group. DETAILED DESCRIPTION

[0039] Example 1 Preparation method of the sequential targeted drug delivery system for treating arthritis of the present invention

[0040] 1. Synthesis of bilirubin-modified chondroitin sulfate (BR-CS)

[0041] Chondroitin sulfate (CS, 0.05 mmol; Sigma-Aldrich, St. Louis, USA), carbodiimide hydrochloride (EDCI, 0.06 mmol; Aladdin, Shanghai, China), 4-dimethylaminopyridine (DMAP, 0.06 mmol; Aladdin, Shanghai, China) and ethylenediamine (EDA, 0.05 mmol; Aladdin, Shanghai, China) were dissolved in N,N-dimethylformamide, reacted under magnetic stirring at room temperature for 24 h, dialyzed in water to remove unreacted ethylenediamine and catalyst, and then freeze-dried to obtain ethylenediamine-modified chondroitin sulfate (CS-EDA).

[0042] Bilirubin (BR, 0.04 mmol; Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), EDCI (0.06 mmol), carbodiimide hydrochloride (EDCI, 0.06 mmol; Aladdin, Shanghai, China) and 4-dimethylaminopyridine (DMAP, 0.06 mmol; Aladdin, Shanghai, China) were dissolved in dimethyl sulfoxide (DMSO) and reacted under magnetic stirring at room temperature for 30 min. Then, the obtained CS-EDA was dissolved in a mixture of DMSO and water (V / V=3:1) and the solution was added to the above reaction solution and reacted under magnetic stirring at 30°C for 48 h (the entire reaction system was protected by nitrogen). After the reaction was completed, the organic reagent was dialyzed in water, and the unreacted BR precipitate was removed by centrifugation (10,000×g for 20 min). The supernatant was lyophilized to obtain BR-modified CS (BR-CS).

[0043] By hydrogen nuclear magnetic resonance spectroscopy ( 1H NMR) was used to verify the BR-CS. Figure 1 It can be seen that BR-CS contains the characteristic peaks of both BR and CS, indicating that BR-CS was successfully obtained.

[0044] 2. Preparation of Liqueflon-Carrying Nanoparticles

[0045] Lipofectamine (27 μmol) was dissolved in dimethyl sulfoxide, and then the solution was added dropwise to the aqueous solution of BR-CS (15 μmol) under stirring. After the addition was completed, stirring was continued for 10 minutes, and then the probe was ultrasonicated for 5 minutes to remove the unencapsulated Lipofectamine, i.e., the Lipofectamine nanoparticles (LCF-CSBN), by ultrafiltration.

[0046] Example 2 Structural Characterization of the Nanoparticles of Licofilon (LCF-CSBN) Prepared by the Present Invention

[0047] The LCF-CSBN obtained above was diluted with pure water until it had a light blue opalescence, and its particle size was measured by a laser particle size analyzer; the zeta potential of the obtained preparation was directly measured without dilution; and its morphology was observed by transmission electron microscopy. At the same time, in order to investigate the responsiveness of LCF-CSBN to ROS in vitro, we also investigated the changes in drug release behavior and particle size of LCF-CSBN in the presence of oxides.

[0048] from Figure 2 It can be seen that the particle size of LCF-CSBN is about 160nm, and the particle size polydispersity index (PDI) is less than 0.3 ( Figure 2 AB). The critical micelle concentration of BR-CS is about 25 μg / mL ( Figure 2 C). LCF-CSBN can be stored at 4°C for at least 1 week ( Figure 2 D). In the presence of ROS, BR in LCF-CSBN can be oxidized in a short time, and its particle size and morphology also change significantly, indicating that LCF-CSBN has obvious ROS-responsive depolymerization ( Figure 2 EG).

[0049] Comparative Example:

[0050] Using amino-terminated PEG instead of CS-EDA, PEG-BR was synthesized according to the method of Example 1. The remaining steps and amounts of substances remained unchanged.

[0051] PEG-BR was used instead of CS-BR, and the nanoparticles LCF-PEGBN were prepared using the method of Example 1. The amount ratio of LCF to PEG-BR was (molar ratio of 27:390), and the other steps remained unchanged.

[0052] The beneficial effects of the present invention are demonstrated by pharmacodynamic tests as follows.

[0053] Test Example 1 In vitro uptake experiment of leukoferrin-carrying nanoparticles of the present invention

[0054] Lipopolysaccharide (LPS) activated RAW 264.7 cells were inoculated on a 12-well cell culture plate and cultured for 24 hours. After the cells adhered to the wall, the culture medium was replaced with a serum-free medium containing DiD-labeled CSBN and PEGBN (DiD concentration was 1μ / ml). After incubation for 4 hours, the fluorescence intensity of the cells was detected by flow cytometry, and the fluorescence distribution of the cells was observed and photographed using a laser confocal microscope. To verify the endocytosis pathway of the nanoparticles, RAW 264.7 cells were pretreated with different inhibitors (0.5mM CS, 30μM chlorpromazine, 60μM amiloride, 5mM M-β-CD or CD44 antibody) for 1 hour, and then DiD-labeled CSBN was added and incubated for another 4 hours. Fibroblasts without inhibitor treatment were used as the control group, and the fluorescence intensity of the cells was detected by flow cytometry.

[0055] from Figure 3 It can be seen that the uptake of CSBN in LPS-activated RAW 264.7 cells is significantly higher than that of PEGBN ( Figure 3 A, C); Furthermore, the co-localization ability of CSBN with the Golgi apparatus of LPS-activated RAW 264.7 cells was significantly higher than that of PEGBN ( Figure 3 B, E). In addition, after pretreatment with CS and CD44 antibodies, the uptake of CSBN on LPS-activated RAW 264.7 cells was significantly reduced ( Figure 3 D). The above results indicate that CSBN can be efficiently taken up by LPS-activated RAW 264.7 cells through CD44 receptor-mediated endocytosis and can be targeted to the Golgi apparatus.

[0056] Experimental Example 2 Investigation of in vitro biological activity

[0057] LPS-activated RAW 264.7 cells were inoculated on a 12-well cell culture plate and cultured for 24 h. After the cells adhered to the wall, LCF solution, CSBN, LCF-CSBN and LCF-PEGBN (the concentration of LCF was 2.7 μM, and the medium without drug was used as the control) were added to the culture medium. After incubation for 3 h, the supernatant was taken and the concentrations of TNF-α, IL-1β, IL-6, iNOS and IL-10 were determined by ELISA. The morphology of the Golgi apparatus of each group of cells was observed by transmission electron microscopy. The Golgi apparatus of the cells was labeled with green fluorescent GM130 antibody, observed by laser confocal microscopy and the fluorescence intensity of the cells was determined by flow cytometry. The reactive oxygen concentration of the cells after LCF-PEGBN treatment was investigated by labeling with 5-(6)-chloromethyl-2,7-dichlorohydrofluorescein diacetate (DCF). GM130 labeling was used to investigate the Golgi stress intensity of cells after LCF-PEGBN treatment; iNOS and CD206 labeling were used to investigate the M1 and M2 macrophage phenotypes of cells after LCF-PEGBN treatment, respectively.

[0058] Depend on Figure 4 It can be seen that compared with other treatment methods, LCF-CSBN treatment can more effectively reduce the concentration of reactive oxygen species in LPS-activated RAW264.7 cells ( Figure 4 AB) and Golgi stress state ( Figure 4 CD). At the same time, LCF-CSBN treatment can efficiently repolarize M1 macrophages to M2 macrophages ( Figure 4 E). Furthermore, LCF-CSBN treatment can significantly reduce the secretion of pro-inflammatory cytokines and provide anti-inflammatory cytokines in LPS-activated RAW 264.7 cells ( Figure 4 F).

[0059] Experimental Example 3 Animal Experiment of Sequential Targeted Drug Delivery System of the Present Invention

[0060] 1) OA rat model

[0061] The rats were anesthetized using a small animal gas anesthesia machine, the hair on their right knee joints was shaved, and they were fixed in a supine position. 50 μL of 40 mg / mL monosodium iodoacetate (MIA) was injected into the right knee joint cavity. When the rat knee joints became swollen and the pain threshold was significantly reduced, the OA rat model was obtained.

[0062] 2) M1 macrophage distribution and enrichment experiment in vivo

[0063] DiD solution and DiD-labeled CSBN and PEGBN were injected into the right knee joint cavity of OA rats through the articular cavity, and the fluorescence intensity of the rat inflammatory joints was observed and photographed by small animal living imaging on the day of injection and 1 day, 2 days, 3 days, 7 days, 14 days, 21 days, and 28 days later. After the small animal living imaging observation, the rats were killed, and the synovium of the inflammatory joints of each group of rats was separated and frozen sections were made. Then, the nuclei and M1 macrophages of the cells in the sections were stained with DAPI and green fluorescent labeled iNOS antibodies, respectively, and observed and photographed by laser confocal microscopy. Figure 5 It can be seen that compared with PEGNP, CSBN can remain in the joints for a long time and can be effectively enriched in the location of M1 macrophages.

[0064] 3) Pharmacodynamics test

[0065] The right knee joints of OA rats were treated with normal saline, LCF solution, blank CSBN, and LCF-CSBN by intra-articular injection. The dose of LCF was 40 μg, and it was administered once. From the first day of administration, the mechanical withdrawal threshold of the right leg of each group of rats was measured once a week.

[0066] Depend on Figure 6 It can be seen that after LCF-CSBN treatment, the number of M1 macrophages in OA joints decreased significantly, while the number of M2 macrophages increased significantly. This result further shows that LCF-CSBN can effectively repolarize M1 macrophages into M2 macrophages. Figure 7 It can be seen that, compared with other methods, LCF-CSBN treatment can more effectively relieve the joint pain of OA rats. These results show that the sequential drug delivery system of the present invention is effective in treating OA.

Claims

1. Use of bilirubin, chondroitin sulfate and lexapro in combination for preparing a drug for treating osteoarthritis.

2. The use according to claim 1, characterized in that: The medicine is a medicine for relieving osteoarthritis joint pain.

3. The use according to claim 1 or 2, characterized in that: The molar ratio of bilirubin, chondroitin sulfate and lexapro is: 1-10 parts of bilirubin, 1-20 parts of chondroitin sulfate, and 0.1-5 parts of lexapro.

4. The use according to claim 3, characterized in that: The molar ratio of bilirubin, chondroitin sulfate and lexapro is: 15 parts of bilirubin, 15 parts of chondroitin sulfate, and 27 parts of lexapro.

5. The use according to any one of claims 1 to 4, characterized in that: The medicine is a preparation for intra-articular administration.

6. A sequential targeted drug delivery system for treating arthritis, characterized in that: It is prepared from bilirubin, chondroitin sulfate and lexapro as raw materials, and the molar ratio of bilirubin, chondroitin sulfate and lexapro is: 1-10 parts of bilirubin, 1-20 parts of chondroitin sulfate, and 0.1-5 parts of lexapro.

7. The sequential targeted drug delivery system for treating arthritis according to claim 6, characterized in that: The molar ratio of bilirubin, chondroitin sulfate and lexapro is: 15 parts of bilirubin, 15 parts of chondroitin sulfate, and 27 parts of lexapro.

8. The sequential targeted drug delivery system for treating arthritis according to claim 6 or 7, characterized in that: The method first modifies chondroitin sulfate with bilirubin, and then encapsulates lexapro in the modified chondroitin sulfate to prepare nanoparticles LCF-CSBN containing lexapro, which is the sequential targeted drug delivery system of the present invention.

9. A method for preparing a sequential targeted drug delivery system for treating arthritis according to any one of claims 6 to 8, comprising the following steps: a. Ethylenediamine-modified chondroitin sulfate First, chondroitin sulfate, carbodiimide hydrochloride, 4-dimethylaminopyridine and ethylenediamine are dissolved in N,N-dimethylformamide, reacted under magnetic stirring at room temperature, dialyzed in water to remove unreacted ethylenediamine and catalyst, and lyophilized to obtain ethylenediamine-modified chondroitin sulfate; b. Bilirubin-modified chondroitin sulfate: Dissolve bilirubin, EDCI, carbodiimide hydrochloride, and 4-dimethylaminopyridine in dimethyl sulfoxide, and react under magnetic stirring at room temperature. Dissolve the chondroitin sulfate modified with ethylenediamine in step a in a mixed solution of DMSO and water, and add the solution to the above reaction solution. React under magnetic stirring at 30° C., and pass nitrogen gas through the entire reaction system for protection. After the reaction is completed, dialyze in water to remove the organic reagent, and then remove the unreacted precipitate by centrifugation. After the supernatant is freeze-dried, the bilirubin-modified chondroitin sulfate is obtained. c. Preparation of Liquefied Nanoparticles: Dissolve levofloxacin in dimethyl sulfoxide, and then add the solution dropwise to the bilirubin-modified chondroitin sulfate aqueous solution prepared in step b under stirring. After the addition is completed, continue stirring, then use probe ultrasound to remove unencapsulated levofloxacin, i.e., levofloxacin nanoparticles (LCF-CSBN), by ultrafiltration.

10. Use of the sequential targeted drug delivery system according to any one of claims 6 to 8 in the preparation of a bone-joint cavity drug for treating osteoarthritis; preferably, the drug is a drug for relieving osteoarthritis joint pain.

Citation Information

Patent Citations

  • Folate-modified chondroitin sulfate-deoxycholic acid polymer as well as synthesis method and application thereof

    CN105380902A

  • Antifungal product combining licofelone and fluconazole and application thereof

    CN106619621A

  • Preparation and application of doxorubicin carrier-free nano drug

    CN109875964A

  • Medical composition for preventive and treatment agent of arthritic disorders

    JP2010037302A